2023
Breast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review
Carrasco-Tenezaca F, Moreira-Dinzey J, Manrai P, Bearse M, Burela S, Podany P, Singh K, Pareja F, Zheng J, Muscato N, Liang Y, Zhan H, Krishnamurti U, Dolezal D, Wang J, Harigopal M. Breast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review. International Journal Of Surgical Pathology 2023, 32: 1037-1045. PMID: 37908113, DOI: 10.1177/10668969231209780.Peer-Reviewed Original ResearchBreast carcinomaTubulopapillary featuresHuman epidermal growth factor 2 (HER2) expressionBreast cancer histologic subtypesNonmetastatic breast carcinomaTriple-negative profileHigh-grade nuclear featuresTriple-negative carcinomasHigh-grade featuresMetastatic breast carcinomaGrowth factor 2 expressionFactor 2 expressionReports of tumorsMicropapillary projectionsNeoadjuvant therapyHistologic subtypeWorse prognosisFirst tumorPoor prognosisAdditional tumorsInvasive carcinomaEstrogen receptorCarcinomaPathogenic variantsTumors
2019
Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li X, Oprea-Ilies G, Wetherilt C, Riaz A, Aleskandarany M, Green A, Ellis I, Cantuaria G, Gupta M, Manne U, Agboola J, Baskovich B, Janssen E, Callagy G, Walsh E, Mehta A, Dogra A, Shet T, Gajaria P, Traina T, Nggada H, Omonisi A, Ahmed S, Rakha E, Rida P, Aneja R. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. Cancers 2019, 11: 995. PMID: 31319547, PMCID: PMC6678933, DOI: 10.3390/cancers11070995.Peer-Reviewed Original ResearchTriple-negative breast cancerAR-positive triple-negative breast cancerAndrogen receptorAR statusPrognostic roleOverall survivalBetter prognosisBreast cancerAR-positive nucleiPatients' overall survivalReliable prognostic markersNegative breast cancerPotential therapeutic targetMulti-institutional studyAR positivityTNBC patientsPoor prognosisPrognostic valuePrimary tumorPatient prognosisIndian cohortPrognostic markerUK cohortAR antibodyTNBC samples
2017
Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer
Ogden A, Garlapati C, Li X, Turaga R, Oprea-Ilies G, Wright N, Bhattarai S, Mittal K, Wetherilt C, Krishnamurti U, Reid M, Jones M, Gupta M, Osan R, Pattni S, Riaz A, Klimov S, Rao A, Cantuaria G, Rida P, Aneja R. Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer. Scientific Reports 2017, 7: 42289. PMID: 28218233, PMCID: PMC5316996, DOI: 10.1038/srep42289.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalTNBC cellsOverall survivalPoor prognosisBreast cancerTriple-negative breast cancer patientsTriple-negative breast cancerMultivariable Cox modelMetastasis-free survivalWorse overall survivalBreast cancer patientsMulti-institutional studyAA TNBC patientsAfrican AmericansAfrican American womenTNBC patientsIndependent biomarkerPrognostic valueCancer patientsWorse outcomesCox modelTissue microarrayKIFC1 knockdownTNBC